We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.52%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$449M
AUM Growth
+$34.2M
Cap. Flow
+$72.9M
Cap. Flow %
16.24%
Top 10 Hldgs %
46.73%
Holding
81
New
13
Increased
18
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
EXC icon
Exelon
EXC
+$28.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.85M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$9.77M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$9.45M
5
ONC
BeOne Medicines Ltd
ONC
+$6.75M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.1M
2
EXEL icon
Exelixis
EXEL
+$10.3M
3
GILD icon
Gilead Sciences
GILD
+$8.27M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$4.64M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$3.44M

Sector Composition

Rank Sector Weight
1 Healthcare 97.78%
2 Utilities 2.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
51
Rocket Pharmaceuticals
RCKT
$397M
$1.38M 0.31%
63,000
– –
KOD icon
52
Kodiak Sciences
KOD
$2.46B
$1.37M 0.31%
16,200
– –
CCXI
53
DELISTED
ChemoCentryx, Inc.
CCXI
$1.31M 0.29%
36,100
-58,200
-62% -$2.04M
DNLI icon
54
Denali Therapeutics
DNLI
$3.94B
$1.16M 0.26%
+26,000
New +$1.23M
IOVA icon
55
Iovance Biotherapeutics
IOVA
$3.74B
$1.11M 0.25%
58,000
– –
FOLD
56
DELISTED
Amicus Therapeutics
FOLD
$1.09M 0.24%
94,600
– –
FULC icon
57
Fulcrum Therapeutics
FULC
$294M
$1.08M 0.24%
+61,000
New +$1.21M
NKTR icon
58
Nektar Therapeutics
NKTR
$2.55B
$905K 0.2%
4,467
– –
BBIO icon
59
BridgeBio Pharma
BBIO
$15.4B
$881K 0.2%
+52,800
New +$2.23M
NBP
60
NovaBridge Biosciences American Depositary Shares
NBP
$219M
$851K 0.19%
18,000
– –
EXAS
61
DELISTED
Exact Sciences
EXAS
$833K 0.19%
10,700
– –
XENE icon
62
Xenon Pharmaceuticals
XENE
$6B
$797K 0.18%
25,500
– –
ALLO icon
63
Allogene Therapeutics
ALLO
$722M
$747K 0.17%
+50,000
New +$882K
PRTA icon
64
Prothena Corp
PRTA
$467M
$741K 0.17%
+15,000
New +$832K
AGIO icon
65
Agios Pharmaceuticals
AGIO
$2.05B
$707K 0.16%
21,500
– –
NKTX icon
66
Nkarta
NKTX
$197M
$617K 0.14%
40,200
-16,245
-29% -$279K
IMVT icon
67
Immunovant
IMVT
$9.05B
$511K 0.11%
60,000
– –
ANAB icon
68
AnaptysBio
ANAB
$1.7B
$348K 0.08%
10,000
– –
GMDA
69
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$271K 0.06%
107,000
– –
BDTX icon
70
Black Diamond Therapeutics
BDTX
$130M
$235K 0.05%
44,000
– –
RLMD icon
71
Relmada Therapeutics
RLMD
$482M
$225K 0.05%
10,000
– –
LEGN icon
72
Legend Biotech
LEGN
$3.99B
$209K 0.05%
4,500
-45,000
-91% -$2.28M
TSVT
73
DELISTED
2seventy bio
TSVT
$94K 0.02%
+3,666
New +$114K
ALLK
74
DELISTED
Allakos
ALLK
– –
-15,700
Closed -$1.66M
AXSM icon
75
Axsome Therapeutics
AXSM
$10.8B
– –
-14,000
Closed -$461K
1 2
3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2021 Portfolio in Review

As of Q4 2021, International Biotechnology Trust held 81 positions worth $449M, up 8.3% from $415M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust deployed $72.9M of net new capital in Q4 2021, opening 13 new positions and adding to 18 existing holdings. Its largest new stake was Exelon: 766,241 shares worth $9.98M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Utilities.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $15.1M trimmed.

  • International Biotechnology Trust's largest Q4 2021 buy was Exelon: 766,241 shares worth $9.98M.
  • International Biotechnology Trust added most to Alnylam Pharmaceuticals in Q4 2021, an estimated $9.85M increase.
  • International Biotechnology Trust's biggest Q4 2021 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $15.1M.
  • International Biotechnology Trust fully exited Exelixis in Q4 2021, selling an estimated $10.3M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $449M portfolio in Q4 2021.
  • International Biotechnology Trust opened 13 new positions and closed 8 in Q4 2021.
  • International Biotechnology Trust's portfolio value rose 8.3% quarter-over-quarter to $449M.

Based on International Biotechnology Trust's 13F filing for Q4 2021, filed 15 Feb 2022.